Drugs / antigen-pulsed dendritic cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00017355 | Apr 2001 → ? | cutaneous melanoma | Baylor Health Care System | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | antigen-pulsed dendritic cell vaccine | “Determine the safety and tolerability of antigen-pulsed dendritic cell vaccine in patients with metastatic melanoma.” NCT00017355 ↗ |
| Known as | antigen-pulsed DC vaccine | “Patients receive priming injections of antigen-pulsed DC vaccine SC once every 2 weeks for 8 weeks.” NCT00017355 ↗ |
| Action | Deplete | “Vaccines made from a patient's white blood cells mixed with tumor antigens may make the body build an immune response to kill tumor cells.” NCT00017355 ↗ |
| Modality | Cell therapy | “These autologous CD34+ hematopoietic progenitor cells are cultured to generate dendritic cells (DC).” NCT00017355 ↗ |
| Route | Subcutaneous | “Patients receive priming injections of antigen-pulsed DC vaccine SC once every 2 weeks for 8 weeks.” NCT00017355 ↗ |